Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Sep;28(3):428–432. doi: 10.1128/aac.28.3.428

Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.

R W Strunk, J C Gratz, R Maserati, W M Scheld
PMCID: PMC180267  PMID: 2934021

Abstract

The efficacy of ciprofloxacin (Bay o 9867), a promising new quinolone, was compared with the efficacy of azlocillin plus tobramycin in rabbits with experimentally induced Pseudomonas aeruginosa endocarditis. The MBCs of ciprofloxacin, azlocillin, and tobramycin against the test strain were 0.5, 8, and 4 micrograms/ml respectively. Ciprofloxacin at a concentration of 50 mg/kg or azlocillin at a concentration of 200 mg/kg in combination with tobramycin at a concentration of 5 mg/kg was administered intramuscularly at 8-h intervals for 4 days. Both regimens produced median peak serum bactericidal titers of 1:8. The concentrations of ciprofloxacin, azlocillin, and tobramycin in serum, 1.8 +/- 0.7, 154 +/- 48, and 9.1 +/- 2.4 micrograms/ml (mean +/- standard deviation), respectively, closely approximated concentrations found in humans after accepted dosages. At the end of treatment, the titers of P. aeruginosa were 3.0 +/- 1.6 log10 CFU/g of vegetation (mean +/- standard deviation) for recipients of ciprofloxacin and 3.2 +/- 1.3 log10 CFU/g of vegetation for recipients of azlocillin plus tobramycin. These values compared with control titers of 7.3 +/- 1.6 CFU/g. These data indicate that at the doses used, ciprofloxacin was as effective as azlocillin plus tobramycin in the treatment of P. aeruginosa endocarditis in rabbits. Since the latter drug combination has proven efficacy, ciprofloxacin deserves further evaluation in the therapy of systemic infections in animal models and in humans.

Full text

PDF
428

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer G., Fekety F. R. Experimental endocarditis due to Pseudomonas aeruginosa. I. Description of a model. J Infect Dis. 1976 Jul;134(1):1–7. doi: 10.1093/infdis/134.1.1. [DOI] [PubMed] [Google Scholar]
  2. Archer G., Fekety F. R., Jr Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J Infect Dis. 1977 Sep;136(3):327–335. doi: 10.1093/infdis/136.3.327. [DOI] [PubMed] [Google Scholar]
  3. Bauernfeind A., Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983 Apr;2(2):111–115. doi: 10.1007/BF02001575. [DOI] [PubMed] [Google Scholar]
  4. Carruthers M. M., Kanokvechayant R. Pseudomonas aeruginosa endocarditis. Report of a case, with review of the literature. Am J Med. 1973 Dec;55(6):811–818. doi: 10.1016/0002-9343(73)90262-3. [DOI] [PubMed] [Google Scholar]
  5. Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fass R. J. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983 Oct;24(4):568–574. doi: 10.1128/aac.24.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Muytjens H. L., van der Ros-van de Repe J., van Veldhuizen G. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid. Antimicrob Agents Chemother. 1983 Aug;24(2):302–304. doi: 10.1128/aac.24.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Neu H. C. Carbenicillin and ticarcillin. Med Clin North Am. 1982 Jan;66(1):61–77. doi: 10.1016/s0025-7125(16)31442-0. [DOI] [PubMed] [Google Scholar]
  9. Reeves D. S., Bywater M. J., Holt H. A., White L. O. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother. 1984 Apr;13(4):333–346. doi: 10.1093/jac/13.4.333. [DOI] [PubMed] [Google Scholar]
  10. Reyes M. P., Lerner A. M. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis. 1983 Mar-Apr;5(2):314–321. doi: 10.1093/clinids/5.2.314. [DOI] [PubMed] [Google Scholar]
  11. Ristuccia A. M., Cunha B. A. The aminoglycosides. Med Clin North Am. 1982 Jan;66(1):303–312. doi: 10.1016/s0025-7125(16)31462-6. [DOI] [PubMed] [Google Scholar]
  12. Sande M. A., Irvin R. G. Penicillin-aminoglycoside synergy in experimental Streptococcus viridans endocarditis. J Infect Dis. 1974 May;129(5):572–576. doi: 10.1093/infdis/129.5.572. [DOI] [PubMed] [Google Scholar]
  13. Scheld W. M., Brodeur J. P., Keeley J. M., Field M. R., Kelly W. J., 4th, Long W. J., Jr, Zak O. Evaluation of azlocillin in vitro and in discriminative animal models of infection. J Antimicrob Chemother. 1983 May;11 (Suppl B):51–68. doi: 10.1093/jac/11.suppl_b.51. [DOI] [PubMed] [Google Scholar]
  14. Scheld W. M., Johnson M. L., Gerhardt E. B., Sande M. A. Clindamycin therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1982 Apr;21(4):646–649. doi: 10.1128/aac.21.4.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Scheld W. M., Valone J. A., Sande M. A. Bacterial adherence in the pathogenesis of endocarditis. Interaction of bacterial dextran, platelets, and fibrin. J Clin Invest. 1978 May;61(5):1394–1404. doi: 10.1172/JCI109057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stevens P., Young L. S. Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother. 1977 Aug;12(2):286–287. doi: 10.1128/aac.12.2.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wenzel R. P., Osterman C. A., Townsend T. R., Veazey J. M., Jr, Servis K. H., Miller L. S., Craven R. B., Miller G. B., Jr, Jackson R. S. Development of a statewide program for surveillance and reporting of hospital-acquired infections. J Infect Dis. 1979 Nov;140(5):741–746. doi: 10.1093/infdis/140.5.741. [DOI] [PubMed] [Google Scholar]
  18. Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wright A. J., Wilson W. R. Experimental animal endocarditis. Mayo Clin Proc. 1982 Jan;57(1):10–14. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES